Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 in narcolepsy type 1 with cataplexy
2024-511998-30-00Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy type 1 (NT1) comparing TAK-861 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in ESS total score. Started Oct 2024; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2024-511998-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511998-30-00.